- The OPN and the ACCP H/O PRN Journal Club is a monthly virtual (online) event. 

Overview

This virtual oncology pharmacy journal club provides an interactive, accredited platform for pharmacists to critically evaluate emerging literature, discuss real-world clinical challenges, and apply evidence-based strategies to patient care. Designed specifically for oncology pharmacists, the program fosters ongoing professional development, enhances therapeutic decision-making, and supports the evolving role of pharmacists within the cancer care team. 

During this presentation, Dr. White will be discussing the primary article that led to the approval of treosulfan in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in the United States. The attendees will explore the trial design, statistical analysis, efficacy and safety data, along with its impact on clinical practice across the country. 

Identified Gap(s)
Oncology pharmacists lack regular, structured opportunities to engage with emerging literature and apply new evidence to clinical practice. The rapid pace of drug development, evolving treatment guidelines, and increasing complexity of oncology care demand ongoing education that is interactive and peer-driven. The absence of oncology-specific journal clubs limits pharmacists’ ability to stay current, critically evaluate research, and contribute fully to multidisciplinary care—ultimately impacting patient outcomes.

Description of Current State
Oncology pharmacists are increasingly stepping into high-value, patient-focused roles due to the growing complexity of cancer care and shortages of oncologists and nurses. With over 50 new cancer drugs approved in 2024 alone, the need for pharmacists to stay current with treatment advances is critical.1 However, educational gaps persist, as pharmacists often lack access to oncology-focused continuing education. As drug experts on the care team, they must be equipped to manage complex therapies and fill care gaps—particularly in areas like pregnancy-associated cancer and supportive care.

Description of desired/achievable state
Oncology pharmacists will have access to a virtual, accredited journal club designed to support continuous learning and clinical application of emerging evidence. This interactive platform will foster peer-to-peer discussion, enhance critical literature appraisal skills, and empower pharmacists to deliver evidence-based care in complex scenarios, ultimately strengthening their role within the oncology care team.

Upon completion of this journal club, you will:

1. Define the role of reduced intensity conditioning (RIC) for patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) receiving allogeneic hematopoietic stem cell transplant (alloHSCT)
2. Analyze the MC FludT.14 trial and the key outcomes associated with treosulfan versus busulfan with fludarabine for reduced intensity conditioning
3. Evaluate the impact of treosulfan on the current alloHSCT preparative regimen landscape

Target Audience

This activity is intended for oncology pharmacists, pharmacy techs, and pharmacy residents who are involved in the treatment of cancer patients.

Presented By